Efficacy and Safety of Trametinib in Non‐V600 BRAF Mutant Melanoma: A Phase II Study

Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)

(2020) Douglas B. Johnson et al.   CLINICAL CANCER RESEARCH

Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations

(2019) Christian Menzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses

(2019) Thomas Botton et al.   Cell Reports

Dual MAPK inhibition is an effective therapeutic strategy for a subset of class II BRAF mutant melanoma

(2018) Matthew Dankner et al.   CLINICAL CANCER RESEARCH

Long-Term Outcomes in Patients With BRAF V600–Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib

(2018) Georgina V. Long et al.   JOURNAL OF CLINICAL ONCOLOGY

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer

(2018) Vivek Subbiah et al.   JOURNAL OF CLINICAL ONCOLOGY

BRAF fusions identified in melanomas have variable treatment responses and phenotypes

(2018) Jacqueline A. Turner et al.   ONCOGENE

Dabrafenib plus trametinib in patients with previously untreated BRAF V600E -mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

(2017) David Planchard et al.   LANCET ONCOLOGY

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

(2017) Ahmet Zehir et al.   NATURE MEDICINE

Targeted agents and immunotherapies: optimizing outcomes in melanoma

(2017) Jason J. Luke et al.   Nature Reviews Clinical Oncology

Clinicopathological features and clinical outcomes associated withTP53andBRAFNon-V600mutations in cutaneous melanoma patients

(2016) Dae Won Kim et al.   CANCER

Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

(2016) Paolo A Ascierto et al.   LANCET ONCOLOGY

Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade

(2016) D. B. Johnson et al.   Cancer Immunology Research

BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition

(2015) Zhan Yao et al.   CANCER CELL

The distribution ofBRAFgene fusions in solid tumors and response to targeted therapy

(2015) Jeffrey S. Ross et al.   INTERNATIONAL JOURNAL OF CANCER

Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia

(2015) Enrico Tiacci et al.   NEW ENGLAND JOURNAL OF MEDICINE

The landscape of kinase fusions in cancer

(2014) Nicolas Stransky et al.   Nature Communications

Acneiform eruptions: A common cutaneous toxicity of the MEK inhibitor trametinib

(2013) Rachael Anforth et al.   AUSTRALASIAN JOURNAL OF DERMATOLOGY

BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK Inhibition

(2013) K. E. Hutchinson et al.   CLINICAL CANCER RESEARCH

BRAF L597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors

(2012) Kimberly Brown Dahlman et al.   Cancer Discovery